Drug intelligence / Profile preview

GF-1006

Development stage: Preclinical
Lead developer: GenFlow Biosciences
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Ophthalmic

Overview

GF-1006 is an mRNA-based therapeutic candidate being developed by GenFlow Biosciences for the treatment of age-related macular degeneration (AMD). The drug utilizes lipid nanoparticle (LNP) technology to deliver mRNA encoding a specific centenarian variant of the Sirtuin 6 (SIRT6) protein. SIRT6 is a key regulator of genomic stability, DNA repair, and longevity; the centenarian variant is associated with exceptional lifespan and enhanced cellular maintenance. By expressing this variant in target ocular tissues, GF-1006 is designed to boost SIRT6 activity, thereby counteracting the oxidative stress and cellular senescence that drive the progression of AMD.

Targets

SIRT6 (Sirtuin 6)

Beyond the preview

Go deeper on GF-1006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GF-1006.

Explore the full profile